Hospital
Munson Healthcare Otsego Memorial Hospital
Munson Healthcare Otsego Memorial Hospital was paid $14.27M by Medicaid between Jan 2018 and Dec 2024, across 236 billing codes. Its largest line is 99285, emergency room visit (most serious) — 18% of everything it billed.
33Billing provider infoMUNSON HEALTHCARE OTSEGO MEMORIAL HOSPITAL
GAYLORD, MI 49735
GAYLORD, MI 49735
33aNPI1124028972assigned 07/22/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.27M
24GClaims529,054
24DCodes billed236
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#56 of 86
Median peer was paid$21.55M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KRUSZKA, BONNIE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 44,164 | $1.65M | |
| 2019 | 72,137 | $1.73M | |
| 2020 | 61,128 | $1.58M | |
| 2021 | 81,609 | $2.31M | |
| 2022 | 92,023 | $2.52M | |
| 2023 | 97,336 | $2.44M | |
| 2024incomplete | 80,657 | $2.04M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 18% | 9,115 | 8,239 | $2.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 13,315 | 11,338 | $2.09M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 16,548 | 14,081 | $1.79M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.4% | 7,949 | 7,326 | $774K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 3,570 | 3,462 | $498K |
| 59025 | Fetal non-stress test | 2.6% | 4,037 | 1,848 | $369K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.5% | 4,017 | 3,208 | $362K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 13,411 | 3,821 | $303K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 2.0% | 6,998 | 2,558 | $284K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.9% | 9,447 | 3,006 | $269K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 7,945 | 6,846 | $260K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.7% | 7,097 | 6,333 | $238K |
224 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 3,567 | $224K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 2,364 | $221K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 848 | $201K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 1.3% | 7,099 | $182K |
| 71045 | Radiologic examination, chest; single view | 1.2% | 4,581 | $176K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 4,682 | $174K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 1,432 | $145K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,604 | $117K |
| 76830 | Ultrasound, transvaginal | <1% | 1,979 | $117K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,813 | $102K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 8,776 | $100K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,677 | $94K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 765 | $84K |
| 80061 | Lipid panel | <1% | 8,334 | $84K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,011 | $81K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 5,780 | $80K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,615 | $79K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,321 | $79K |
| 97162 | <1% | 1,337 | $75K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,339 | $75K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 1,386 | $73K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 567 | $68K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 224 | $67K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 160 | $63K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,482 | $61K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,163 | $60K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,504 | $59K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 540 | $57K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,318 | $56K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 36,529 | $53K |
| 80053 | Comprehensive metabolic panel | <1% | 24,307 | $52K |
| 74018 | <1% | 1,687 | $52K | |
| 73564 | <1% | 1,352 | $48K | |
| G0378 | Hospital observation service, per hour | <1% | 538 | $47K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,986 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 7,535 | $41K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 710 | $40K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 731 | $39K |
| 73630 | <1% | 2,015 | $39K | |
| 86900 | <1% | 3,148 | $37K | |
| 73610 | <1% | 1,614 | $33K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,078 | $32K |
| 72110 | <1% | 821 | $31K | |
| 73130 | <1% | 1,691 | $30K | |
| 76801 | <1% | 523 | $30K | |
| 76642 | <1% | 710 | $28K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,944 | $28K |
| 73030 | <1% | 1,241 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 7,849 | $25K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 234 | $23K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,754 | $20K |
| 73110 | <1% | 941 | $20K | |
| 76536 | <1% | 363 | $19K | |
| 82607 | <1% | 3,595 | $19K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 246 | $19K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 161 | $18K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 105 | $18K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,424 | $17K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 92 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,514 | $16K |
| 36415 | Collection of venous blood by venipuncture | <1% | 49,722 | $16K |
| 86850 | <1% | 3,864 | $15K | |
| 82728 | <1% | 2,716 | $14K | |
| 87653 | <1% | 964 | $14K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,182 | $14K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,829 | $13K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,986 | $13K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,104 | $13K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 964 | $11K |
| 82746 | <1% | 1,984 | $11K | |
| 97166 | <1% | 219 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,008 | $11K |
| 86780 | <1% | 1,746 | $10K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 415 | $10K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,938 | $10K |
| 74019 | <1% | 232 | $10K | |
| 96367 | <1% | 321 | $10K | |
| 84439 | <1% | 3,055 | $9K | |
| 73502 | <1% | 466 | $8K | |
| 83735 | <1% | 7,715 | $8K | |
| 72100 | <1% | 175 | $8K | |
| 84702 | <1% | 1,957 | $8K | |
| 77065 | Tomosynthesis, mammo | <1% | 193 | $7K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 350 | $7K |
| 87077 | <1% | 2,699 | $7K | |
| 87186 | <1% | 2,588 | $7K | |
| 83540 | <1% | 2,598 | $6K | |
| 87340 | <1% | 1,746 | $6K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 502 | $5K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 414 | $5K |
| 83550 | <1% | 1,386 | $4K | |
| 86762 | <1% | 1,124 | $4K | |
| 73560 | <1% | 175 | $4K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 648 | $4K |
| 97161 | <1% | 97 | $4K | |
| 93017 | <1% | 66 | $4K | |
| 81003 | <1% | 13,196 | $4K | |
| 92523 | <1% | 27 | $4K | |
| 81025 | <1% | 6,854 | $3K | |
| 86803 | <1% | 708 | $3K | |
| 93971 | <1% | 63 | $3K | |
| 87631 | <1% | 627 | $3K | |
| 93975 | <1% | 26 | $3K | |
| 87070 | <1% | 1,140 | $3K | |
| 83880 | <1% | 1,125 | $3K | |
| 71271 | <1% | 53 | $3K | |
| 87015 | <1% | 990 | $3K | |
| 80076 | <1% | 2,793 | $3K | |
| 86140 | <1% | 2,346 | $3K | |
| 85027 | <1% | 1,129 | $2K | |
| 77066 | Tomosynthesis, mammo | <1% | 40 | $2K |
| 85610 | <1% | 5,200 | $2K | |
| 82570 | <1% | 1,299 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 181 | $2K |
| 87210 | <1% | 1,157 | $2K | |
| 87480 | <1% | 260 | $2K | |
| 87510 | <1% | 260 | $2K | |
| 87088 | <1% | 787 | $2K | |
| 82043 | <1% | 1,108 | $2K | |
| 87660 | <1% | 259 | $2K | |
| 87634 | <1% | 124 | $2K | |
| 72141 | <1% | 13 | $2K | |
| 97016 | <1% | 363 | $2K | |
| 86901 | <1% | 3,146 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 330 | $2K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $2K |
| 82950 | <1% | 780 | $2K | |
| 74022 | <1% | 116 | $2K | |
| 00790 | <1% | 13 | $2K | |
| 85652 | <1% | 2,373 | $1K | |
| 84481 | <1% | 185 | $1K | |
| 73221 | <1% | 14 | $1K | |
| 87205 | <1% | 954 | $1K | |
| 76770 | <1% | 24 | $1K | |
| 81001 | <1% | 3,490 | $1K | |
| 83690 | <1% | 5,236 | $1K | |
| 97165 | <1% | 31 | $1K | |
| 84460 | <1% | 504 | $1K | |
| 84450 | <1% | 489 | $968.99 | |
| 85730 | <1% | 3,876 | $919.98 | |
| 00731 | <1% | 12 | $751.92 | |
| 86481 | <1% | 12 | $726.87 | |
| 12001 | <1% | 62 | $711.41 | |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 14 | $708.03 |
| 86039 | <1% | 162 | $662.40 | |
| 73080 | <1% | 57 | $644.76 | |
| 01967 | Neuraxial labor analgesia/anesthesia for planned vaginal delivery | <1% | 12 | $627.56 |
| 73140 | <1% | 29 | $600.42 | |
| 83001 | <1% | 81 | $583.87 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 170 | $565.59 |
| 86038 | <1% | 122 | $553.40 | |
| 86787 | <1% | 160 | $530.67 | |
| 84153 | <1% | 94 | $505.45 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,797 | $457.87 |
| 72040 | <1% | 12 | $433.26 | |
| 82670 | <1% | 40 | $418.89 | |
| 72072 | <1% | 12 | $407.82 | |
| 76942 | <1% | 46 | $392.26 | |
| 86430 | <1% | 156 | $355.79 | |
| 82150 | <1% | 368 | $343.21 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 517 | $306.12 |
| 81002 | <1% | 237 | $301.51 | |
| 87522 | Neg quan hep c or qual rna | <1% | 16 | $294.63 |
| 73590 | <1% | 15 | $289.98 | |
| 73090 | <1% | 13 | $288.84 | |
| 84146 | <1% | 39 | $268.22 | |
| 85379 | <1% | 1,154 | $260.86 | |
| 87807 | <1% | 111 | $244.49 | |
| 87040 | <1% | 1,480 | $228.81 | |
| 84484 | <1% | 3,351 | $178.89 | |
| 84703 | <1% | 857 | $178.13 | |
| 99406 | <1% | 13 | $176.40 | |
| 83615 | <1% | 98 | $160.50 | |
| 0240U | <1% | 327 | $142.63 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 51 | $142.63 |
| 84403 | <1% | 20 | $132.36 | |
| 82784 | <1% | 40 | $128.90 | |
| 82565 | <1% | 86 | $115.80 | |
| 84402 | <1% | 18 | $113.90 | |
| 83002 | <1% | 14 | $103.88 | |
| 83605 | <1% | 1,669 | $96.28 | |
| 86709 | <1% | 12 | $90.94 | |
| 83516 | <1% | 13 | $80.15 | |
| 84100 | <1% | 132 | $79.95 | |
| 83655 | <1% | 14 | $66.26 | |
| 86706 | <1% | 12 | $51.69 | |
| 87045 | <1% | 12 | $36.18 | |
| 85007 | <1% | 27 | $31.49 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,016 | $31.35 |
| 82962 | <1% | 115 | $28.13 | |
| 82550 | <1% | 40 | $21.79 | |
| 82947 | <1% | 12 | $18.18 | |
| 88304 | <1% | 184 | $13.86 | |
| 82272 | <1% | 26 | $11.40 | |
| 85014 | <1% | 12 | $9.21 | |
| 85018 | <1% | 12 | $9.21 | |
| 82140 | <1% | 13 | $8.52 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,527 | $1.44 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 2,473 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 51 | $0.00 |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 853 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 411 | $0.00 |
| 84145 | 0% | 223 | $0.00 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | 0% | 301 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 13 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 13 | $0.00 |
| 94729 | 0% | 12 | $0.00 | |
| 82542 | 0% | 41 | $0.00 | |
| 90715 | 0% | 14 | $0.00 | |
| 87530 | 0% | 21 | $0.00 | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 0% | 17 | $0.00 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,725 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 1,020 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 803 | $0.00 |
| 94761 | 0% | 3,947 | $0.00 | |
| 96376 | 0% | 2,103 | $0.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 1,710 | $0.00 |
| A9270 | Non-covered item or service | 0% | 47 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 239 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 165 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 69 | $0.00 |
| 96368 | 0% | 15 | $0.00 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKRUSZKA, BONNIE (COO MUNSON PHYSICIAN NETWORK)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.